# A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects

> **NCT00117247** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Anemia
- Congestive Heart Failure

## Interventions

- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT00117247
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** — (—)
- **Last updated:** 2009-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117247, "A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00117247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*